Company Filing History:
Years Active: 2023
Title: Yixiang Xu: Innovator in Therapeutic Antibodies
Introduction
Yixiang Xu is a prominent inventor based in Emeryville, CA (US). He has made significant contributions to the field of therapeutic antibodies, particularly in targeting CD22, a protein associated with certain types of cancers.
Latest Patents
Yixiang Xu holds a patent titled "Constructs targeting CD22 and uses thereof." This patent describes antibodies, specifically single chain variable fragment (scFv) antibodies, and constructs that bind to the extracellular domain of CD22. The patent outlines methods for using these constructs in the therapeutic treatment of diseases characterized by CD22 expression, such as B-cell lymphomas and leukemias.
Career Highlights
Yixiang Xu is currently associated with Eureka Therapeutics, Inc., where he continues to advance research in the field of immunotherapy. His work focuses on developing innovative solutions for treating cancers that express CD22.
Collaborations
Yixiang Xu collaborates with notable colleagues, including Jun Cui and Pengbo Zhang, who contribute to the research and development efforts at Eureka Therapeutics, Inc.
Conclusion
Yixiang Xu's work in developing therapeutic antibodies targeting CD22 represents a significant advancement in cancer treatment. His innovative approach and collaboration with fellow researchers highlight the importance of teamwork in scientific discovery.